Protagonist Therapeutics, Inc.
(NASDAQ : PTGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -6.80%149.190.0%$1383.97m
NVAXNovavax, Inc. -11.71%74.7478.2%$513.10m
AMGNAmgen, Inc. -2.51%222.001.4%$499.88m
BIIBBiogen, Inc. -0.16%220.171.8%$495.99m
GILDGilead Sciences, Inc. -1.49%67.491.0%$484.70m
BNTXBioNTech SE -1.06%145.930.0%$409.11m
REGNRegeneron Pharmaceuticals, Inc. -1.85%609.902.7%$395.28m
ILMNIllumina, Inc. -2.94%355.183.3%$367.71m
VRTXVertex Pharmaceuticals, Inc. -1.07%225.651.9%$337.32m
SNSSSunesis Pharmaceuticals, Inc. 0.00%2.650.7%$185.24m
EXASEXACT Sciences Corp. -2.55%72.1417.9%$164.35m
ARNAArena Pharmaceuticals, Inc. -0.54%89.9913.7%$130.66m
INCYIncyte Corp. -0.94%74.092.4%$128.96m
ALNYAlnylam Pharmaceuticals, Inc. -1.99%133.698.2%$122.51m
BMRNBioMarin Pharmaceutical, Inc. -0.51%84.224.2%$102.65m

Company Profile

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.